(Q38160410)

30 August 2017

title

Teriflunomide: a review of its use in relapsing multiple sclerosis (English)

1 reference

30 August 2017

1

Karly P Garnock-Jones

1 reference

30 August 2017

publication date

1 December 2013

1 reference

30 August 2017

1 reference

30 August 2017

volume

27

1 reference

30 August 2017

issue

12

1 reference

30 August 2017

page(s)

1103-1123

1 reference

Pathophysiology of multiple sclerosis and the place of teriflunomide

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0118-2

Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0118-2

Immune mechanisms of new therapeutic strategies in MS: teriflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0118-2

Leflunomide: a review of its use in active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0118-2

Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0118-2

The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0118-2

Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0118-2

Leflunomide interferes with pyrimidine nucleotide biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0118-2

Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0118-2

Randomized trial of oral teriflunomide for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0118-2

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0118-2

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0118-2

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0118-2

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0118-2

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0118-2

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0118-2

Multiple Sclerosis Therapies: Molecular Mechanisms and Future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0118-2

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide

21 January 2018

1 reference

12 December 2020

Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the dark agouti rat model of experimental autoimmune encephalomyelitis

1 reference

12 December 2020

1 reference

12 December 2020

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

1 reference

12 December 2020

Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.

1 reference

12 December 2020

The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.

1 reference

12 December 2020

Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial

1 reference

12 December 2020

Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents

1 reference

12 December 2020

Regulation of B cell function by the immunosuppressive agent leflunomide

1 reference

12 December 2020

10.1007/S40263-013-0118-2

Identifiers

DOI

1 reference

30 August 2017

1 reference